$LYEL 3 SEC Filings

Filed On	Filing
10 Sep 2026	Form 3: Aguirre Jarrad Mattieu, Chief Medical Officer Holds 20,279 shares of Common Stock
18 Jun 2026	Form 3: Innovative Cellular Therapeutics Holdings Ltd, 10% owner Holds 3,000,000 shares of Common Stock
16 Mar 2026	Form 3: Shah Smital, Chief Fin. and Bus. Officer No securities owned
10 Nov 2025	Form 3: Bulis Veronica Sanchez, VP, Corporate Controller Holds 9,452 shares of Common Stock
29 Jul 2025	Form 3: Arch Venture Fund XIII, L.p., 10% owner and 7 others Holds 938,438 shares of Common Stock
11 Jun 2025	Form 3: Bachleda Mark, Director No securities owned
11 Jun 2025	Form 3: Meltz Mark A, General Counsel No securities owned
11 Jun 2025	Form 3: Shook David, Chief Medical Officer No securities owned
01 Nov 2024	Form 3: Ramachandra Sumant, Director No securities owned
20 Jul 2023	Form 3: Lang Matthew, Chief Business Officer No securities owned
03 Oct 2022	Form 3: Thompson Rahsaan, Chief Legal Officer No securities owned
29 Mar 2022	Form 3: Albertson Tina M., Chief Medical Officer
04 Feb 2022	Form 3: Lee Gary K., Chief Scientific Officer No securities owned
17 Jun 2021	Form 3: Glaxosmithkline Plc, 10% owner
16 Jun 2021	Form 3: Arch Venture Partners IX, Llc, 10% owner and 6 others
16 Jun 2021	Form 3: Turner Heather D, Chief General Counsel
16 Jun 2021	Form 3: Seely Lynn, Director
16 Jun 2021	Form 3: Rieflin William Jl, Director
16 Jun 2021	Form 3: Newton Charles W., Chief Financial Officer
16 Jun 2021	Form 3: Nelsen Robert, Director

Comments